eISSN: 3023-6940
  • Home
  • Comparison of serum c-reactive protein levels between benign prostate hyperplasia and prostate cancer in patients undergoing prostate biopsy

Original Research

Comparison of serum c-reactive protein levels between benign prostate hyperplasia and prostate cancer in patients undergoing prostate biopsy


1 Ordu Üniversitesi Tıp Fakültesi, Biyokimya Bölümü, Ordu, Türkiye

2 Ankara Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara, Türkiye


DOI :
2016; 11 (3): 10-15

Abstract

Objective: It has been argued that prostate cancer may have an association with inflamma-tion. Prostate specific antigen is widely used for di-agnosis, treatment, and follow-up of prostate can-cer. C-reactive protein is a widely utilized marker of inflammation. We compared serum CRP values between benign prostate hyperplasia (BPH) and prostate cancer (PCa) diagnosed by prostate biop-sy performed in patients with a tPSA level greater than 4.0 ng/dl.

Material and Methods: Serum CRP and sedi-mentation rate were retrospectively assessed in 182 patients who had a tPSA level above 4.0 ng/dl and were scheduled to undergo prostate biopsy. Pa-thology results of 175 patients could be accessed. CRP levels of patients with BPH and PCa were compared with each other using Wilcoxon-Mann Whitney U and Kruskal Wallis tests. A p value of less than 0.05 was considered statistically signifi-cant.

Results: Both the analyses taking a CRP cut-off level of 0.5 mg/dl and quantitative serum CRP levels failed to show any significant difference be-tween the BPH group (0.59+0.11 mg/dl) and the PCa group (0.55+0.18 mg/dl) (p=0.779; p=0.192). Sedimentation rate was also similar in the BPH and PCa groups (18.98 mm/hour vs 18.18 mm/hour; p=0.870).

Conclusion: Our study could not demon-strate any significant difference between serum CRP levels of patients with BPH and PCa.

Key Words: PSA, Prostate biopsy, CRP, BPH, Prostate cancer


Abstract

Objective: It has been argued that prostate cancer may have an association with inflamma-tion. Prostate specific antigen is widely used for di-agnosis, treatment, and follow-up of prostate can-cer. C-reactive protein is a widely utilized marker of inflammation. We compared serum CRP values between benign prostate hyperplasia (BPH) and prostate cancer (PCa) diagnosed by prostate biop-sy performed in patients with a tPSA level greater than 4.0 ng/dl.

Material and Methods: Serum CRP and sedi-mentation rate were retrospectively assessed in 182 patients who had a tPSA level above 4.0 ng/dl and were scheduled to undergo prostate biopsy. Pa-thology results of 175 patients could be accessed. CRP levels of patients with BPH and PCa were compared with each other using Wilcoxon-Mann Whitney U and Kruskal Wallis tests. A p value of less than 0.05 was considered statistically signifi-cant.

Results: Both the analyses taking a CRP cut-off level of 0.5 mg/dl and quantitative serum CRP levels failed to show any significant difference be-tween the BPH group (0.59+0.11 mg/dl) and the PCa group (0.55+0.18 mg/dl) (p=0.779; p=0.192). Sedimentation rate was also similar in the BPH and PCa groups (18.98 mm/hour vs 18.18 mm/hour; p=0.870).

Conclusion: Our study could not demon-strate any significant difference between serum CRP levels of patients with BPH and PCa.

Key Words: PSA, Prostate biopsy, CRP, BPH, Prostate cancer